SCHEMBL1022912

SCHEMBL1022912

CCC[C](O)CCC

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5188324 0.86
SCHEMBL9518949 0.86
SCHEMBL11688591 0.84 HDAC3 (0.44)
SCHEMBL302492 0.84
SCHEMBL270308 0.81
SCHEMBL19212465 0.80 GPR84 (0.55)
SCHEMBL10541073 0.75 CES1 (0.50)
SCHEMBL1200789 0.73
SCHEMBL42275 0.73
SCHEMBL3402330 0.73 HDAC3 (0.50)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040220223-A1 Novel human NK3 receptor-selective antagonist compounds, method for obtaining them and pharmaceutical compositions containing them SANOFI-AVENTIS (FR) 2004-11-04 US claimed
US-20020049329-A1 Novel human NK3 receptor-selective antagonist compounds, method for obtaining them and pharmaceutical compositions containing them SANOFI-AVENTIS (FR) 2002-04-25 US claimed
US-6291672-B1 FOR THE PREPARATION OF DRUGS USEFUL IN THERAPY OF PSYCHIATRIC DISEASES, DISEASES OF PSYCHOSOMATIC ORIGIN, HYPERTENSION SANOFI-SYNTHELABO (FR) 2001-09-18 US claimed
US-6028082-A FOR TRATING PSYCHOLOGICAL DISORDERS SANOFI-SYNTHELABO (FR) 2000-02-22 US claimed
EP-0625509-B1 N-alkyl substituted piperidine-derivatives with neurokinin receptor antagonist activity ZENECA LTD (GB) 1997-07-30 EP claimed
US-5521199-A TREATMENT OF ASTHMA ZENECA LIMITED (GB) 1996-05-28 US claimed
EP-0625509-A1 N-alkyl substituted piperidine-derivatives with neurokinin receptor antagonist activity ZENECA LIMITED (GB) 1994-11-23 EP claimed
EP-3492104-B1 USE OF 10H-BENZO [G] PTERIDIN-2,4-DION DERIVATIVES TRIOPTOTEC GMBH (DE) 2023-02-15 EP disclosed
CN-110799345-B Tamper-resistant media for thermal printing 欧米亚国际集团 2022-04-19 CN disclosed
EP-3838902-A1 10H-BENZO[G]PTERIDINE-2,4-DIONE DERIVATIVES, METHOD FOR PRODUCING SAME AND USE OF SAME TriOptoTec GmbH (DE) 2021-06-23 EP disclosed
EP-2723743-B1 10H-BENZO[G]PTERIDINE-2,4-DIONE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF TRIOPTOTEC GMBH (DE) 2019-08-14 EP disclosed
EP-3135110-B1 1,7-DIARYL-1,6-HEPTADIEN-3,5-DION DERIVATIVES, METHODS OF MAKING AND USING THE SAME TRIOPTOTEC GMBH (DE) 2019-07-10 EP disclosed
EP-3492104-A1 USE OF 10H-BENZO [G] PTERIDIN-2,4-DION DERIVATIVES Trioptotec GmbH (DE) 2019-06-05 EP disclosed
EP-0625509-B1 N-alkyl substituted piperidine-derivatives with neurokinin receptor antagonist activity ZENECA LTD (GB) 1997-07-30 EP disclosed
EP-0463400-B1 Transparencies XEROX CORP (US) 1997-04-02 EP disclosed
US-5521199-A TREATMENT OF ASTHMA ZENECA LIMITED (GB) 1996-05-28 US disclosed
EP-0625509-A1 N-alkyl substituted piperidine-derivatives with neurokinin receptor antagonist activity ZENECA LIMITED (GB) 1994-11-23 EP disclosed
US-5202205-A TRANSPARENCIES COMPRISING METAL HALIDE OR UREA ANTISTATIC LAYER XEROX CORPORATION (US) 1993-04-13 US disclosed
EP-0463400-A1 Transparencies XEROX CORPORATION (US) 1992-01-02 EP disclosed
US-4251507-A USING CELLULOSIC COMPOUNDS DOMINION PHARMACAL, INC. (US) 1981-02-17 US disclosed